Litcius/Paper detail

Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial

Yao‐Chun Hsu, Chi-Yi Chen, I‐Wei Chang, Chi‐Yang Chang, Chun‐Ying Wu, Teng‐Yu Lee, Ming‐Shiang Wu, Ming‐Jong Bair, Jyh-Jou Chen, Chieh‐Chang Chen, Cheng‐Hao Tseng, Chi‐Ming Tai, Yen‐Tsung Huang, Wen‐Hui Ku, Lein‐Ray Mo, Jaw‐Town Lin

2021The Lancet Infectious Diseases59 citationsDOI

Topics & Concepts

MedicineDouble blindTenofovirAlanine aminotransferasePlaceboChronic hepatitisInternal medicineClinical trialGastroenterologyVirologyVirusHuman immunodeficiency virus (HIV)Alternative medicinePathologyHepatitis B Virus StudiesHepatitis C virus researchLiver Disease Diagnosis and Treatment
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial | Litcius